Saint Joseph's University Medical Center, Paterson, NJ, USA.
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:2324709621992207. doi: 10.1177/2324709621992207.
Immune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with immunotherapy. Limited literature is available regarding hyperprogression in hepatocellular cancer. We report a case of a 36-year-old male with no past medical history who presented with nausea, vomiting, and abdominal pain and was diagnosed with unresectable hepatocellular cancer and thereby started on atezolizumab and bevacizumab. The patient got only 1 cycle of treatment and unfortunately had hyperprogression of disease.
免疫检查点抑制剂在多种恶性肿瘤中作为一种新的治疗方法出现；然而，它与一系列被称为免疫相关不良事件的独特副作用相关。超进展是指接受免疫治疗的患者疾病负担的加速增长。关于肝细胞癌的超进展，文献有限。我们报告了一例 36 岁男性病例，无既往病史，表现为恶心、呕吐和腹痛，被诊断为不可切除的肝细胞癌，随后开始接受阿替利珠单抗和贝伐珠单抗治疗。患者仅接受了 1 个周期的治疗，不幸的是疾病出现了超进展。
